What Does Xeris Pharmaceuticals Inc (NASDAQ: XERS) Gaining 25.32% Over the Week Mean?

Xeris Pharmaceuticals Inc (NASDAQ: XERS) was up 2.4% in the pre-market today, and its current share price is $3.75. Over the past week, this stock has gained 25.32%. Despite showing the red graphs, XERS is still among the top biotechnology stocks at the moment. According to Investors Observer, this stock has a 46 rating, meaning that its score is better than 46% of other similar stocks. The market capitalization of XERS is $248.86M, and its volume today is 3.16 million. This stock traded within the range of $3.71 – $4.12 throughout the day on Monday. 

XERS could be the next stock to pump up 

According to a popular analyst, Illinois headquartered company Xeris Pharmaceuticals stock could be the next stock that might blow up. This company specializes in liquid injectable drug therapies commercialization activities. At the moment, it is working on the commercialization of treatments for epilepsy and hypoglycemia. 

There has been some recent buzz among investors for this stock as the company acquired Strongbridge Pharmaceuticals, the commercial stage pharma firm looking to treat rare diseases. This merger is expected to close by the end of this year. The transaction, according to the company, has been unanimously approved apart from the M.D. Jeffrey W. Sherman. 

With the closure of this transaction, the current shareholders of XERS will own 60% of the combined company, while the rest of the percentage will be held by the present shareholders of Strongbridge.

Popular investment influencer’s formula that might also work for XERS

According to Will Meade, a former hedge fund manager and popular investment influencer, “XERS is likely to squeeze next.” Why does he say so? According to his formula, small market cap + low share price +high short interest, XERS might be the next. Even though the formula he used isn’t a fool-proof one, but the metrics he’s using are strong indicators highlighting short squeeze. With XERS, 23.3% of the float is short. RBC Capital, in the meanwhile, has a “Buy” rating for XERS, with a price point of $10. 

Leave a Comment

Your email address will not be published.